Allergy and risk of hematologic malignancies: Associations and mechanisms

Leukemia Research

Volumn 38, Issue 10, 2014, Pages 1137-1144

  Musolino, C ^a   Allegra, A ^a   Minciullo, P L ^b   Gangemi, S ^b,c  

^a UNIVERSITY OF MESSINA   (Italy)

^b UNIVERSITY OF MESSINA   (Italy)

^c CNR   (Italy)

Author keywords

Allergic dysregulation; Hematologic malignancies; Immune system; T cell tolerance

Indexed keywords

CLEMASTINE; CORTICOSTEROID; DESLORATADINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ALLERGY; ASTHMA; CANCER RISK; DISEASE ASSOCIATION; DRUG MECHANISM; FOOD ALLERGY; HEMATOLOGIC MALIGNANCY; HODGKIN DISEASE; HUMAN; IMMUNE SYSTEM; IMMUNOMODULATION; MULTIPLE MYELOMA; NONHODGKIN LYMPHOMA; REVIEW; RISK FACTOR; SEX; SOLID TUMOR; WALDENSTROEM MACROGLOBULINEMIA; ALLERGIC DYSREGULATION; ANIMAL; HEMATOLOGIC DISEASE; HEMATOLOGIC MALIGNANCIES; HYPERSENSITIVITY; IMMUNOLOGY; T CELL TOLERANCE;

ALLERGIC DYSREGULATION; HEMATOLOGIC MALIGNANCIES; IMMUNE SYSTEM; T CELL TOLERANCE;

ANIMALS; HEMATOLOGIC NEOPLASMS; HUMANS; HYPERSENSITIVITY; RISK FACTORS;

EID: 84907997972     PISSN: 01452126     EISSN: 18735835     Source Type: Journal    
DOI: 10.1016/j.leukres.2014.08.004     Document Type: Review

References (104)

1. Li L., Boussiotis V.A. Control and regulation of peripheral tolerance in allergic inflammatory disease: therapeutic consequences. Chem Immunol Allergy 2008, 94:178-188.
2. Martin D.N., Mikhail I.S., Landgren O. Autoimmunity and hematologic malignancies: associations and mechanisms. Leuk Lymphoma 2009, 50:541-550.
3. Turner M.C., Epidemiology: Allergy history, IgE, and cancer. Cancer Immunol Immunother 2012, 61:1493-1510.
4. Soderberg K.C., Jonsson F., Winqvist O., et al. Autoimmune diseases, asthma and risk of haematological malignancies: a nationwide case-control study in Sweden. Eur J Cancer 2006, 42:3028-3033.
5. Mirabelli M.C., Zock J.P., D'Errico A., et al. Occupational exposure to high molecular weight allergens and lymphoma risk among Italian adults. Cancer Epidemiol Biomark Prev 2009, 18:2650-2654.
6. Becker N., de Sanjose S., Nieters A., et al. Birth order, allergies and lymphoma risk: results of the European collaborative research project Epilymph. Leuk Res 2007, 31:1365-1372.
7. Ellison-Loschmann L., Benavente Y., Douwes J., et al. Immunoglobulin E levels and risk of lymphoma in a case-control study in Spain. Cancer Epidemiol Biomark Prev 2007, 16:1492-1498.
8. Melbye M., Smedby K.E., Lehtinen T., et al. Atopy and risk of non-Hodgkin lymphoma. J Natl Cancer Inst 2007, 99:158-166.
9. Magnani C., Pastore G., Luzzatto L., Terracini B. Parental occupation and other environmental factors in the etiology of leukemias and non-Hodgkin's lymphomas in childhood: a case-control study. Tumori. 1990, 76:413-419.
10. Rudant J., Orsi L., Monnereau A., et al. Childhood hodgkin's lymphoma, non-Hodgkin's lymphoma and factors related to the immune system: the escale study (SFCE). Int J Cancer 2011, 129:2236-2247.
11. Linabery A.M., Jurek A.M., Duval S., et al. The association between atopy and childhood/adolescent leukemia: a meta-analysis. Am J Epidemiol 2010, 171:749-764.
12. Rudant J., Orsi L., Menegaux F., et al. Childhood acute leukemia, early common infections, and allergy: the ESCALE Study. Am J Epidemiol 2010, 172:1015-1027.
13. Brown L.M., Gridley G., Check D., et al. Risk of multiple myeloma and monoclonal gammopathy of undetermined significance among white and black male United States veterans with prior autoimmune, infectious, inflammatory, and allergic disorders. Blood 2008, 111:3388-3394.
14. Shadman M., White E., De Roos A.J., Walte R.B. Associations between allergies and risk of hematologic malignancies: results from the VITamins and lifestyle cohort study. Am. J. Hematol 2013, 88:1050-1054. 2013.
15. Koshiol J., Lam T.K., Gridley G., et al. Racial differences in chronic immune stimulatory conditions and risk of non-Hodgkin's lymphoma in veterans from the United States. J Clin Oncol 2011, 29:378-385.
16. Gutensohn N., Cole P. Childhood social environment and Hodgkin's disease. N Engl J Med 1981, 304:135-140.
17. Hjalgrim H., Smedby K.E., Rostgaard K., et al. Infectious mononucleosis, childhood social environment, and risk of Hodgkin lymphoma. Cancer Res 2007, 67:2382-2388.
18. Fabbro-Peray P., Daures J.P., Rossi J.F. Environmental risk factors for non-Hodgkin's lymphoma: a population-based case-control study in Languedoc-Roussillon, France. Cancer Causes Control 2001, 12:201-212.
19. Kristinsson S.Y., Koshiol J., Bjorkholm M., et al. Immune-related and inflammatory conditions and risk of lymphoplasmacytic lymphoma or Waldenstrom macroglobulinemia. J Natl Cancer Inst 2010, 102:557-567.
20. Soderberg K.C., Hagmar L., Schwartzbaum J., et al. Allergic conditions and risk of hematological malignancies in adults: a cohort study. BMC Public Health 2004, 4:51.
21. Chang J.S., Tsai Y.-W., Tsai C.R., Wiemels J.L., Allergy Risk of Childhood Acute Lymphoblastic Leukemia: a Population-based and Record-based Study. Am J Epidemiol 2011, 176:970-978.
22. Nunez-Enriquez J.C., Fajardo-Gutierrez A., Buchan-Duran E.P., et al. Allergy and acute leukaemia in children with Down syndrome: a population study. Report from the Mexican inter-institutional group for the identification of the causes of childhood leukaemia. Br J Cancer 2013, 108:2334-2338.
23. Kusters M., Verstegen R.H.J., Gemen E.F., De Vries E. Intrinsic defect of the immune system in children with Down syndrome: a review. Clin Exp Immunol 2009, 156:189-193.
24. Aryanl Z., Rezaei N. Comment on 'Allergy and acute leukaemia in children with Down syndrome: a population study. Report from the Mexican Inter Institutional Group for the Identification of the Causes of Childhood Leukaemia (MIGICCL)' - is increased surveillance by hypersensitive immune system a reality or myth?. Br J Cancer 2013, 109:1386-1388.
25. Mejia-Arangure J.M., Fajardo-Gutierrez A., Flores-Aguilar H., et al. Environmental factors contributing to the development of childhood leukemia in children with Down's syndrome. Leukemia 2003, 17:1905-1907.
26. Mejia-Arangure J.M., Fajardo-Gutierrez A., Perez-Saldivar M.L., et al. Magnetic fields and acute leukemia in children with Down syndrome. Epidemiology 2007, 18:158-161.
27. Schaub B., Liu J., Hoppler S., et al. Impairment of T-regulatory cells in cord blood of atopic mothers. J Allergy Clin Immunol 2008, 121:1491-1499.
28. Amoudruz P., Holmlund U., Malmstrom V., et al. Neonatal immune responses to microbial stimuli: is there an influence of maternal allergy?. J Allergy Clin Immunol 2005, 115:1304-1310.
29. Chang J.S., Buffler P.A., Metayer C., et al. Maternal immunoglobulin E and childhood leukemia. Cancer Epidemiol Biomarkers Prev 2009, 18:2221-2227.
30. Erber E., Lim U., Maskarinec G., et al. Common immune-related risk factors and incident non-Hodgkin lymphoma: the multiethnic cohort. Int J Cancer 2009, 125:1440-1445.
31. Schuz J., Morgan G., Bohler E., Kaatsch P., Michaelis J. Atopic disease and childhood acute lymphoblastic leukemia. Int J Cancer 2003, 105:255-260.
32. Spector L., Groves F., DeStefano F., et al. Medically recorded allergies and the risk of childhood acute lymphoblastic leukaemia. Eur J Cancer 2004, 40:579-584.
33. Rosenbaum P.F., Buck G.M., Brecher M.L. Allergy and infectious disease histories and the risk of childhood acute/lymphoblastic leukaemia. Paediatr Perinat Epidemiol 2005, 19:152-164.
34. Hughes A.M., Lightfoot T., Simpson J., et al. Allergy and risk of childhood leukaemia: results from the UKCCS. Int J Cancer 2007, 121:819-824.
35. Lariou M.S., Dikalioti S.K., Dessypris N., et al. Allergy and risk of acute lymphoblastic leukemia among children: a nationwide case control study in Greece. Cancer Epidemiol 2013, 37:146-151.
36. Dikalioti S.K., Ellen T., Chang E.T., et al. Allergy-associated symptoms in relation to childhood non-Hodgkin's as contrasted to Hodgkin's lymphomas: a case-control study in Greece and meta-analysis. Eur J Cancer 2012, 48:1860-1870.
37. Vajdic C.M., Falster M.O., de Sanjose S., et al. Atopic disease and risk of non-Hodgkin lymphoma: an InterLymph pooled analysis. Cancer Res 2009, 69:6482-6489.
38. Landgren O., Zhang Y., Hoar Zahm S., Inskip P., Zheng T., Baris D. Risk of multiple myeloma following medication use and medical conditions: a case-control study in connecticut women. Cancer Epidemiol Biomark Prev 2006, 15:2342-2347.
39. De Roos A.J., Mirick D.K., Edlefsen K.L., et al. Markers of B-cell activation in relation to risk of non-Hodgkin lymphoma. Cancer Res 2012, 72:4733-4743.
40. Romagnani S. The increased prevalence of allergy and the hygiene hypothesis: missing immune deviation, reduced immune suppression, or both?. Immunology 2004, 112:352-363.
41. Coelho V., Krysov S., Steele A., et al. Identification in CLL of circulating intraclonal subgroups with varying B-cell receptor expression and function. Blood 2013, 122:2664-2672.
42. Kashuba E., Eagle G.L., Bailey J., et al. Proteomic analysis of B-cell receptor signaling in chronic lymphocytic leukaemia reveals a possible role for kininogen. J Proteomics 2013, 8:478-485.
43. Agathangelidis A., Darzentas N., Hadzidimitriou A., et al. Stereotyped B-cell receptors in one-third of chronic lymphocytic leukemia: a molecular classification with implications for targeted therapies. Blood 2012, 119:4467-4475.
44. Sutton L.A., Kostareli E., Stalika E., et al. Temporal dynamics of clonal evolution in chronic lymphocytic leukemia with stereotyped IGHV4-34/IGKV2-30 Antigen Receptors: longitudinal immunogenetic evidence. Mol Med 2013, 19:230-236.
45. Loughran TP Clonal diseases of large granular lymphocytes. Blood 1993, 82:1-14.
46. Zhang D., Loughran T.P. Large granular lymphocytic leukemia: molecular pathogenesis, clinical manifestations, and treatment. Hematol Am Soc Hematol Educ Program 2012, 2012:652-659.
47. Epling-Burnette P.K., Liu J.H., Catlett-Falcone R., et al. Inhibition of STAT3 signaling leads to apoptosis of leukemic large granular lymphocytes and decreased Mcl-1 expression. J Clin Invest 2001, 107:351-362.
48. Shah M.V., Zhang R., Irby R., et al. Molecular profiling of LGL leukemia reveals role of sphingolipid signaling in survival of cytotoxic lymphocytes. Blood 2008, 112:770-781.
49. Zhang R., Shah M.V., Yang J., et al. Network model of survival signaling in large granular lymphocyte leukemia. Proc Natl Acad Sci U S A 2008, 105:16308-16313.
50. Liu X., Ryland L., Yang J., et al. Targeting of survivin by nanoliposomal ceramide induces complete remission in a rat model of NK-LGL leukemia. Blood 2010, 116:4192-4201.
51. Liao A., Broeg K., Fox T., et al. Therapeutic efficacy of FTY720 in a rat model of NK-cell leukemia. Blood 2011, 118:2793-2800.
52. Epling-Burnette P.K., Bai F., Wei S., et al. ERK couples chronic survival of NK cells to constitutively activated Ras in lymphoproliferative disease of granular lymphocytes (LDGL). Oncogene 2004, 23:9220-9229.
53. Schade A.E., Wlodarski M.W., Maciejewski J.P. Pathophysiology defined by altered signal transduction pathways: the role of JAK-STAT and PI3K signaling in leukemic large granular lymphocytes. Cell Cycle 2006, 5:2571-2574.
54. Schade A.E., Powers J.J., Wlodarski M.W., Maciejewski J.P. Phosphatidylinositol-3-phosphate kinase pathway activation protects leukemic large granular lymphocytes from undergoing homeostatic apoptosis. Blood 2006, 107:4834-4840.
55. Koskela H., Ellonen P., Eldfors S., et al. Somatic STAT3 mutations in large granular lympocyte leukemia. N Engl J Med 2012, 366:1905-1913.
56. Landgren O., Linet M.S., McMaster M.L., Gridley G., Hemminki K., Goldin L.R. Familial characteristics of autoimmune and hematologic disorders in 8,406 multiple myeloma patients: a population-based case-control study. Int J Cancer 2006, 118:3095-3098.
57. Lewis D.R., Pottern L.M., Brown L.M., et al. Multiple myeloma among blacks and whites in the United States: the role of chronic antigenic stimulation. Cancer Causes Control 1994, 5:529-539.
58. Morgan G.J., Davies F.E., Linet M. Myeloma aetiology and epidemiology. Biomed Pharmacother 2002, 56:223-234.
59. Gregersen H., Pedersen G., Svendsen N., Thulstrup A.M., Sorensen H.T., Schonheyder H.C. Multiple myeloma following an episode of community-acquired pneumococcal bacteraemia or meningitis. Acta Pathol Microbiol Immunol Scand 2001, 109:797-800.
60. Preuss K.D., Held G., Kubuschok B., et al. Identification of antigenic targets of paraproteins by expression cloning does not support a causal role of chronicantigenic stimulation in the pathogenesis of multiple myeloma and MGUS. Int J Cancer 2007, 121:459-461.
61. Wang H., Diepgen T.L. Is atopy a protective or a risk factor for cancer? A review of epidemiological studies. Allergy 2005, 60:1098-1111.
62. Prescott S.L., Macaubas C., Holt B.J., et al. Transplacental priming of the human immune system to environmental allergens: universal skewing of initial T cell responses toward the Th2 cytokine profile. J Immunol 1998, 160:4730-4737.
63. Chang J.S., Wiemels J.L., Chokkalingam A.P., et al. Genetic polymorphisms in adaptive immunity genes and childhood acute lymphoblastic leukemia. Cancer Epidemiol Biomark Prev 2010, 19:2152-2163.
64. Allan S.E., Broady R., Gregori S., et al. CD4+ T-regulatory cells: toward therapy for human diseases. Immunol Rev 2008, 223:391-421.
65. Chang J.S., Zhou M., Buffler P.A., et al. Profound deficit of IL10 at birth in children who develop childhood acute lymphoblastic leukemia. Cancer Epidemiol Biomark Prev 2011, 20:1736-1740.
66. Kondo N., Kobayashi Y., Shinoda S., et al. Reduced interferon gamma production by antigen-stimulated cord blood mononuclear cells is a risk factor of allergic disorders: 6-year follow-up study. Clin Exp Allergy 1998, 28:1340-1344.
67. Neaville W.A., Tisler C., Bhattacharya A., et al. Developmental cytokine response profiles and the clinical and immunologic expression of atopy during the first year of life. J Allergy Clin Immunol 2003, 112:740-746.
68. Breen E.C., Hussain S.K., Magpantay L., et al. B-cell stimulatory cytokines and markers of immune activation are elevated several years prior to the diagnosis of systemic AIDS-associated non-Hodgkin B-cell lymphoma. Cancer Epidemiol Biomark Prev 2011, 20:1303-1314.
69. Widney D., Gundapp G., Said J.W., et al. Aberrant expression of CD27 and soluble CD27 (sCD27) in HIV infection and in AIDS-associated lymphoma. Clin Immunol 1999, 93:114-123.
70. Breen E.C., Fatahi S., Epeldegui M., Boscardin W.J., Detels R., Martinez-Maza O. Elevated serum soluble CD30 precedes the development of AIDS-associated non-Hodgkin's B cell lymphoma. Tumour Biol 2006, 27:187-194.
71. Widney D.P., Gui D., Popoviciu L.M., et al. Expression and function of the chemokine, CXCL13, and its receptor, CXCR5, in aids-associated non-Hodgkin's lymphoma. AIDS Res Treat 2010, 2010:164586.
72. Greaves M. Infection, immune responses and the aetiology of childhood leukaemia. Nat Rev Cancer 2006, 6:193-203.
73. Strachan D.P. Hay fever, hygiene, and household size. Br Med J 1989, 299:1259-1260.
74. Jourdan-Da Silva N., Perel Y., Mechinaud F., et al. Infectious diseases in the first year of life, perinatal characteristics and childhood acute leukaemia. Br J Cancer 2004, 90:139-145.
75. Schuz J., Kaletsch U., Meinert R., et al. Association of childhood leukaemia with factors related to the immune system. Br J Cancer 1999, 80:585-590.
76. Nishi M., Miyake H. A case-control study of non-T cell acute lymphoblastic leukaemia of children in Hokkaido, Japan. J Epidemiol Community Health 1989, 43:352-355.
77. Petridou E., Trichopoulos D., Kalapothaki V., et al. The risk profile of childhood leukaemia in Greece: a nationwide case-control study. Br J Cancer 1997, 76:1241-1247.
78. Wen W., Shu X.O., Linet M.S., et al. Allergic disorders and the risk of childhood acute lymphoblastic leukemia. Cancer Causes Control 2000, 11:303-307.
79. Holt P.G., Strickland D.H. Interactions between innate and adaptive immunity in asthma pathogenesis: new perspectives from studies on acute exacerbations. J Allergy Clin Immunol 2010, 125:963-972.
80. Schmiegelow K., Vestergaard T., Nielsen S.M., Hjalgrim H. Etiology of common childhood acute lymphoblastic leukemia: the adrenal hypothesis. Leukemia 2008, 22:2137-2141.
81. Holly E.A., Lele C., Bracci P.M., McGrath M.S. Case-control study of non-Hodgkin's lymphoma among women and heterosexual men in the San Francisco Bay Area California. Am J Epidemiol 1999, 150:375-389.
82. Hellstrand K. Histamine in cancer immunotherapy: a preclinical background. Semin Oncol 2002, 29:35-40.
83. Perz J.B., Ho A.D. Histamine dihydrochloride for the treatment of acute myeloid leukemia, malignant melanoma and renal cell carcinoma. Future Oncol 2008, 4:169-177.
84. Yang L.P., Perry C.M. Histamine dihydrochloride: in the management of acute myeloid leukaemia. Drugs 2011, 71:109-122.
85. Brandes L.J., LaBella F.S., Warrington R.C. Increased therapeutic index of antineoplastic drugs in combination with intracellular histamine antagonists. J Natl Cancer Inst 1991, 83:1329-1336.
86. Vermeer M.H., Willemze R. Is mycosis fungoides exacerbated by fluoxetine?. J Am Acad Dermatol 1996, 35:635-636.
87. Johansen P., Senti G. Medication with antihistamines impairs allergen-specific immunotherapy in mice. Clin Exp Allergy 2008, 38:512-519.
88. Johansen P., Weiss A., Bünter A., et al. Clemastine causes immune suppression through inhibition of extracellular signal-regulated kinase-dependent proinflammatory cytokines. J Allergy Clin Immunol 2011, 128:1286-1294.
89. Döbbeling U., Waeckerle-Men Y., Zabel F., Graf N., Kündig T.M., Johansen P. The antihistamines clemastine and desloratadine inhibit STAT3 and c-Myc activities and induce apoptosis in cutaneous T-cell lymphoma cell lines. Exp Dermatol 2013, 22:119-124.
90. Prizment A.E., Anderson K.E., Visvanathan K. Folsom AR Inverse association of eosinophil count with colorectal cancer incidence: atherosclerosis risk in communities study. Cancer Epidemiol Biomark Prev 2011, 20:1861-1864.
91. Maisonneuve P., Lowenfels A.B., Bueno-de-Mesquita H.B., et al. Past medical history and pancreatic cancer risk: results from a multicenter case-control study. Ann Epidemiol 2010, 20:92-98.
92. Lupo P.J., Zhou R., Skapek S.X., et al. Allergies, atopy, immune-related factors and childhood rhabdomyosarcoma: a report from the children's oncology group. Int J Cancer 2014, 134:431-436.
93. Lebecque S., Dolecek C., Laffer S., et al. Immunologic characterization of monoclonal antibodies that modulate human IgE binding to the major birch pollen allergen Bet v 1. J Allergy Clin Immunol 1997, 99:374-384.
94. Yip Y.L., Smith G., Koch J., et al. Identification of epitope regions recognized by tumor inhibitory and stimulatory anti-ErbB-2 monoclonal antibodies: implications for vaccine design. J Immunol 2001, 166:5271-5278.
95. Knittelfelder R., Riemer A.B., Jensen-Jarolim E. Mimotope vaccination-from allergy to cancer. Expert Opin Biol Ther 2009, 9:493-506.
96. Josephs D.H., Spicer J.F., Karagiannis P., Gould H.J., Karagiannis S.N. IgE immunotherapy: a novel concept with promise for the treatment of cancer. Monoclon Antib 2014, 1:54-72.
97. Turner M.C., Chen Y., Krewski D., et al. Cancer mortality among US men and women with asthma and hay fever. Am J Epidemiol 2005, 162:212-221.
98. Karagiannis P., Singer J., Hunt J., et al. Characterisation of an engineered trastuzumab IgE antibody and effector cell mechanisms targeting FlER2/neu-positive tumour cells. Cancer Immunol Immunother 2009, 58:915-930.
99. Neuchrist C., Kornfehl J., Grasl M., et al. Distribution of immunoglobulins in squamous cell carcinoma of the head and neck. Int Arch Allergy Immunol 1994, 104:97-100.
100. Fu S.L., Pierre J., Smith-Norowitz T.A., et al. Immunoglobulin E antibodies from pancreatic cancer patients mediate antibody-dependent cell-mediated cytotoxicity against pancreatic cancer cells. Clin Exp Immunol 2008, 153:401-409.
101. Nagy E., Berczi I., Sehon A.H. Growth inhibition of murine mammary carcinoma by monoclonal IgE antibodies specific for the mammary tumor virus. Cancer Immunol Immunother 1991, 34:63-69.
102. Kershaw M.H., Darcy P.K., Trapani J.A., et al. Tumor-specific IgE-mediated inhibition of human colorectal carcinoma xenograft growth. Oncol Res 1998, 10:133-142.
103. Gould H.J., Mackay G.A., Karagiannis S.N., et al. Comparison of IgE and IgG antibody-dependent cytotoxicity in vitro and in a SCID mouse xenograft model of ovarian carcinoma. Eur J Immunol 1999, 29:3527-3537.
104. Lilienfeld A.M. Practical limitations of epidemiologic methods. Environmental Health Perspectives. 1983, 52:3-8.